Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Targeted Therapy With Vedolizumab and Adalimumab or Ustekinumab in Moderate to Severe Crohn's Disease
NCT06045754Phase 4Active, not recruiting
- Sponsor
- Takeda
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, open-label trial of vedolizumab in Crohn's disease (3 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants With an Endoscopic Response Based on the Simple Endoscopic Score for Crohn's Disease (SES-CD) at 26 weeks and Percentage of Participants With an Endoscopic Response Based on the SES-CD at 52 weeks. Started Apr 2024; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06045754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045754.